Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Donati, M.
Right arrow Articles by Cevenini, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Donati, M.
Right arrow Articles by Cevenini, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 407-410
© 2002 The British Society for Antimicrobial Chemotherapy

Comparative in vitro activity of garenoxacin against Chlamydia spp.

M. Donati, G. M. Pollini, M. Sparacino, M. T. Fortugno, E. Laghi and R. Cevenini*

Sezione di Microbiologia, DMCSS, University of Bologna, Policlinico S.Orsola-Malpighi, via Massarenti 9, 40138, Bologna, Italy

Received 2 January 2002; returned 21 March 2002; revised 30 May 2002; accepted 13 June 2002

The in vitro susceptibilities of 33 isolates of Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci to a new quinolone drug, garenoxacin (BMS-284756), in comparison with levofloxacin, ciprofloxacin, doxycycline, erythromycin and roxithromycin, were determined. Garenoxacin was the most active of the quinolone drugs tested, with identical MIC and MBC, which ranged from 0.007 to 0.03 mg/L. The MIC and MBC of the other two quinolones tested, levofloxacin and ciprofloxacin, were also identical, ranging from 0.25 to 2 mg/L. The MICs and MBCs of doxycycline, erythromycin and roxithromycin were also determined.

* Corresponding author. Tel: +39-051-4290913; Fax: +39-051-341632; E-mail: cevenini{at}almadns.unibo.it


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Med MicrobiolHome page
F. Petrovay and E. Balla
Two fatal cases of psittacosis caused by Chlamydophila psittaci
J. Med. Microbiol., October 1, 2008; 57(10): 1296 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 Vet Rec.Home page
A. Di Francesco, M. Donati, M. Rossi, S. Pignanelli, A. Shurdhi, R. Baldelli, and R. Cevenini
Tetracycline-resistant Chlamydia suis isolates in Italy
Vet Rec., August 23, 2008; 163(8): 251 - 252.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
G. Krishna, J. C. Kisicki, S. Olsen, D. M. Grasela, and Z. Wang
The Effect of Omeprazole on the Bioavailability and Safety of Garenoxacin in Healthy Volunteers
J. Clin. Pharmacol., May 1, 2007; 47(5): 628 - 632.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Donati, K. Di Leo, M. Benincasa, F. Cavrini, S. Accardo, A. Moroni, R. Gennaro, and R. Cevenini
Activity of Cathelicidin Peptides against Chlamydia spp.
Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1201 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
F. Blasi
Atypical pathogens and respiratory tract infections
Eur. Respir. J., July 1, 2004; 24(1): 171 - 182.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. P. Smith, A. L. Baltch, W. J. Ritz, A. N. Carpenter, T. A. Halse, and L. H. Bopp
In Vitro Activities of Garenoxacin and Levofloxacin against Chlamydia pneumoniae Are Not Affected by Presence of Mycoplasma DNA
Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2081 - 2084.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Ameyama, Y. Shinmura, and M. Takahata
Inhibitory Activities of Quinolones against DNA Gyrase of Chlamydia pneumoniae
Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2327 - 2329.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.